

Application No.: 09/686,020  
Amendment dated September 22, 2003  
Reply to Office Action of April 21, 2003

**Amendments to the Claims:**

*This listing of claims will replace all prior versions, and listings, of claims in the application:*

**Listing of Claims:**

Claims 1-32 (canceled)

33. (currently amended) A method of treating ~~an CCX CKR-mediated condition~~ a CCX Chemokine Receptor (CCX CKR)-mediated condition in a mammal comprising administering to the mammal an agent that inhibits or promotes the binding of CCX CKR to ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1 $\gamma$  (murine macrophage inflammatory protein 1 $\gamma$ ), or vMIPII (viral macrophage inflammatory protein II) in a cell or tissue in the mammal, whereby inhibition or promotion of binding ameliorates the CCX CKR-mediated condition.

34. (previously presented) The method of claim 33, wherein the agent inhibits the binding of CCX CKR to ELC, SLC, TECK, BLC, CTACK, mMIP-1 $\gamma$  or vMIPII.

35. (currently amended) The method of claim 33, wherein the CCX CKR-mediated condition is selected from the group consisting of inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an infectious disease ~~or~~ and an immunosuppressive disease.

36. (previously presented) The method of claim 35, wherein the CCX CKR-mediated condition is inflammation.

37. (previously presented) The method of claim 33, wherein the agent promotes the binding of CCX CKR to ELC, SLC TECK, BLC, CTACK, mMIP-1 $\gamma$ , or vMIPII.

38. (withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is an allergic disease.

39. (withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is an autoimmune disease.

40. (withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is graft rejection.

41. (withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is cancer.

42. (withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is an infectious disease.

43. (withdrawn) The method of claim 35, wherein the CCX CKR-mediated condition is an immunosuppressive disease.

44. (previously presented) The method of claim 33, wherein the mammal is a human.

45. (previously presented) The method of claim 33, wherein the mammal is a non-human primate.

46. (previously presented) The method of claim 33, wherein the agent is an antibody.

47. (previously presented) The method of claim 34, wherein  
the mammal is a human; and  
the CCX CKR-mediated condition is selected from the group consisting of  
inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an  
infectious disease or an immunosuppressive disease.

48. (previously presented) The method of claim 37, wherein  
the mammal is a human; and  
the CCX CKR-mediated condition is selected from the group consisting of  
inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an  
infectious disease or an immunosuppressive disease.